Does lurbinectedin's use affect breastfeeding?

In short: Safety of breastfeeding with lurbinectedin is not well established. There are no solid data in humans showing whether the drug passes into breast milk, and because lurbinectedin is a cytotoxic chemotherapy agent with potential serious adverse effects, most clinicians advise avoiding breastfeeding during treatment and for some period after the last dose. The exact withdrawal period should come from the drug’s label or your oncology team.

What you can do:
- Talk with your oncologist or a pharmacist about the recommended washout period for lurbinectedin in your country/clinic.
- If you are currently breastfeeding, discuss whether you should pump and discard milk during therapy or if you should stop breastfeeding altogether.
- If you are planning to start or continue breastfeeding, discuss risks and alternatives with your clinician.

If you’d like, tell me your country or the exact product labeling you’re using, and I can help look for the specific guidance. I’m not a doctor—please consult your healthcare provider for medical advice tailored to you.